Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile
Ilaria Lucca, Laurent Derré, Valérie Cesson, Perrine Bohner, François Crettenand, Sonia Rodrigues-Dias, Florence Dartiguenave, Audrey Masnada, Carla Texeira-Pereira, Sulayman Benmerzoug, Mathieu Chevalier, Sonia Domingos-Pereira, Sylvain Nguyen, Lenka Polak, Anna Schneider, Beat Roth, Patrice Jichlinski, Denise Nardelli-Haefliger, Ilaria Lucca, Laurent Derré, Valérie Cesson, Perrine Bohner, François Crettenand, Sonia Rodrigues-Dias, Florence Dartiguenave, Audrey Masnada, Carla Texeira-Pereira, Sulayman Benmerzoug, Mathieu Chevalier, Sonia Domingos-Pereira, Sylvain Nguyen, Lenka Polak, Anna Schneider, Beat Roth, Patrice Jichlinski, Denise Nardelli-Haefliger
Abstract
Standard-of-care immunotherapy for non-muscle-invasive bladder cancer (NMIBC) with intravesical Bacillus Calmettte-Guérin (BCG) is associated with adverse events (AEs), disease recurrence/progression, and supply shortages. Preclinical data have shown that intravesical instillation of Ty21a/Vivotif, the oral vaccine against typhoid fever, may be an effective and safer alternative to BCG. We assessed the safety of intravesical Ty21a in NMIBC. For ethical reasons, patients with low- or intermediate-risk NMIBC not requiring BCG immunotherapy were enrolled. To determine the maximum tolerated dose, escalating doses of Ty21a/Vivotif were intravesically instilled in three patients once a week for 4 wk in phase 1a. In phase 1b, ten patients received the selected dose (1 × 108 CFU) once a week for 6 wk, as for standard BCG therapy. At this dose, all patients completed their treatment. Most patients experienced minor systemic AEs, while half reported mild local bladder AEs. AEs only occurred after one or two instillations for 40% of the patients. Ty21a bacteria were only recovered in three out of 72 urinary samples at 1 wk after instillation. Intravesical Ty21a might be well tolerated with no cumulative side effects, no fever >39 °C, and lower risk of bacterial persistence than with BCG. Ty21a treatment thus warrants clinical trials to explore its safety and antitumor efficacy in high-risk NMIBC. This trial is registered on ClinicalTrials.gov as NCT03421236.
Patient summary: We examined the safety of a new intra-bladder immunotherapy for non-muscle-invasive bladder cancer as an alternative to the standard BCG treatment. Our data show that the Ty21a vaccine might be well tolerated. Further studies are needed to determine the safety and antitumor efficacy of this treatment.
Keywords: Intravesical microbial immunotherapy; Non–muscle-invasive bladder cancer; Phase 1 trial; Salmonella Ty21a.
© 2022 The Authors.
Figures
References
- Kamat A.M., Hahn N.M., Efstathiou J.A., et al. Bladder cancer. Lancet. 2016;388:2796–2810.
- Gontero P., Bohle A., Malmstrom P.U., et al. The role of bacillus Calmette-Guerin in the treatment of non–muscle-invasive bladder cancer. Eur Urol. 2010;57:410–429.
- Babjuk M., Bohle A., Burger M., et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.
- Mostafid A.H., Palou Redorta J., Sylvester R., Witjes J.A. Therapeutic options in high-risk non–muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin. Eur Urol. 2015;67:359–360.
- Germanier R., Fürer E. Isolation and characterization of galE mutant Ty 21a of Salmonella typhi. A candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975;131:553–558.
- Guzman C.A., Borsutzky S., Griot-Wenk M., et al. Vaccines against typhoid fever. Vaccine. 2006;24:3804–3811.
- Domingos-Pereira S., Cesson V., Chevalier M.F., Derre L., Jichlinski P., Nardelli-Haefliger D. Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer. Oncoimmunology. 2017;6:e1265720.
- Domingos-Pereira S., Sathiyanadan K., La Rosa S., et al. Intravesical Ty21a vaccine promotes dendritic cells and T cell-mediated tumor regression in the MB49 bladder cancer model. Cancer Immunol Res. 2019;7:621–629.
- Summerhayes I.C., Franks L.M. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst. 1979;62:1017–1023.
- Orihuela E., Herr H.W., Pinsky C.M., Whitmore W.F., Jr. Toxicity of intravesical BCG and its management in patients with superficial bladder tumors. Cancer. 1987;60:326–333.
- Berry D.L., Blumenstein B.A., Magyary D.L., Lamm D.L., Crawford E.D. Local toxicity patterns associated with intravesical bacillus Calmette-Guerin: a Southwest Oncology Group study. Int J Urol. 1996;3:98–100.
- van der Meijden A.P., Sylvester R.J., Oosterlinck W., Hoeltl W., Bono A.V. EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol. 2003;44:429–434.
- Koch G.E., Smelser W.W., Chang S.S. Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them. Urology. 2021;149:11–20.
- Gilman R.H., Hornick R.B., Woodard W.E., et al. Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis. 1977;136:717–723.
- Ipe D.S., Horton E., Ulett G.C. The basics of bacteriuria: strategies of microbes for persistence in urine. Front Cell Infect Microbiol. 2016;6:14.
- Mathai E., John T.J., Rani M., et al. Significance of Salmonella typhi bacteriuria. J Clin Microbiol. 1995;33:1791–1792.
- Durek C., Richter E., Basteck A., et al. The fate of bacillus Calmette-Guerin after intravesical instillation. J Urol. 2001;165:1765–1768.
Source: PubMed